

Status: Currently Official on 14-Feb-2025  
 Official Date: Official as of 01-May-2018  
 Document Type: USP Monographs  
 DocId: GUID-EF31325A-341D-4005-BD93-D8D43B04CBF3\_3\_en-US  
 DOI: [https://doi.org/10.31003/USPNF\\_M26090\\_03\\_01](https://doi.org/10.31003/USPNF_M26090_03_01)  
 DOI Ref: v1zt1

© 2025 USPC  
 Do not distribute

## Dihydroergotamine Mesylate Injection

### DEFINITION

Dihydroergotamine Mesylate Injection is a sterile solution of Dihydroergotamine Mesylate in Water for Injection. It contains NLT 90.0% and NMT 110.0% of the labeled amount of dihydroergotamine mesylate ( $C_{33}H_{37}N_5O_5 \cdot CH_4O_3S$ ).

### IDENTIFICATION

#### • A.

**Sample solution:** 2 mL of Injection in 25 mL water

**Acceptance criteria:** The UV absorption spectrum of the *Sample solution* exhibits maxima and minima at the same wavelengths as those of a similar solution of [USP Dihydroergotamine Mesylate RS](#).

### ASSAY

#### • PROCEDURE

**Diluent:** 10 mg/mL of tartaric acid in water

**Solution A:** Dissolve 250 mg of *p*-dimethylaminobenzaldehyde in a cooled mixture of 130 mL of sulfuric acid and 70 mL of water, and add 0.40 mL of ferric chloride solution (1 in 20).

**Standard solution:** 50 µg/mL of [USP Dihydroergotamine Mesylate RS](#) in *Diluent*

**Sample solution:** Nominally 50 µg/mL of dihydroergotamine mesylate from a suitable volume of Injection containing NLT 5 mg of dihydroergotamine mesylate in *Diluent*

**Blank:** *Diluent*

#### Instrumental conditions

**Mode:** Vis

**Analytical wavelength:** 585 nm

**Cell:** 1 cm

#### Analysis

**Samples:** *Standard solution*, *Sample solution*, and *Blank*

Transfer 5.0 mL each of the *Standard solution*, the *Sample solution*, and the *Blank* to separate 50-mL conical flasks. Add 10.0 mL of *Solution A* to each flask, shake, and allow to stand for 30 min. Measure the absorbance of the resulting *Standard solution* and *Sample solution* against the *Blank*.

Calculate the percentage of the labeled amount of dihydroergotamine mesylate ( $C_{33}H_{37}N_5O_5 \cdot CH_4O_3S$ ) in the portion of Injection taken:

$$\text{Result} = (A_U/A_S) \times (C_S/C_U) \times 100$$

$A_U$  = absorbance of the *Sample solution*

$A_S$  = absorbance of the *Standard solution*

$C_S$  = concentration of [USP Dihydroergotamine Mesylate RS](#) in the *Standard solution* (µg/mL)

$C_U$  = nominal concentration of dihydroergotamine mesylate in the *Sample solution* (µg/mL)

**Acceptance criteria:** 90.0%–110.0%

### SPECIFIC TESTS

- **BACTERIAL ENDOTOXINS TEST (85):** NMT 175.0 USP Endotoxin Units/mg of dihydroergotamine mesylate
- **pH (791):** 3.4–4.9
- **OTHER REQUIREMENTS:** It meets the requirements in [Injections and Implanted Drug Products \(1\)](#).

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in single-dose containers, preferably of Type I glass, and protect from light.
- **USP REFERENCE STANDARDS** (11).  
[USP Dihydroergotamine Mesylate RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
DIHYDROERGOTAMINE MESYLATE INJECTION	<a href="#">Documentary Standards Support</a>	SM42020 Small Molecules 4

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. Information currently unavailable

Current DocID: GUID-EF31325A-341D-4005-BD93-D8D43B04CBF3\_3\_en-US

Previous DocID: GUID-EF31325A-341D-4005-BD93-D8D43B04CBF3\_1\_en-US

DOI: [https://doi.org/10.31003/USPNF\\_M26090\\_03\\_01](https://doi.org/10.31003/USPNF_M26090_03_01)

DOI ref: [v1zt1](#)

OFFICIAL